EMTRICITABINE / TENOFOVIR DISOPROXIL KRKA
Form
Film-coated tablets
Content
200 mg/245 mg
Indications
Treatment of HIV-1 infection
Emtricitabine/Tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.
Pre-exposure prophylaxis (PrEP)
Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for preexposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
Important note
Emtricitabine/Tenofovir disoproxil Krka must be prescribed exclusively by a medical specialist.
